Ultragenyx Pharmaceutical Investors Face April 6, 2026 Deadline for Securities Class Action

Faruqi & Faruqi, LLP reminds Ultragenyx Pharmaceutical investors of a securities class action deadline on April 6, 2026. The complaint alleges that the company and its executives violated federal securities laws by making false and/or misleading statements about the effects of setrusumab on patients with osteogenesis imperfecta. The Phase III Orbit study failed to achieve statistical significance, causing the stock price to fall by over 25% and 42%. Investors may move to serve as lead plaintiff or choose to remain absent class members.